Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned.
- Author:
Dae Ho LEE
1
;
Vichien SRIMUNINNIMIT
;
Rebecca CHENG
;
Xin WANG
;
Mauro ORLANDO
Author Information
- Publication Type:Original Article
- Keywords: Biological markers; Non-small-cell lung carcinoma; Epidermal growth factor receptor
- MeSH: Asian Continental Ancestry Group; Biological Markers; Carcinoma, Non-Small-Cell Lung*; Drug Therapy; Epidermal Growth Factor*; Humans; Practice Guidelines as Topic; Prevalence; Receptor, Epidermal Growth Factor*
- From:Cancer Research and Treatment 2015;47(4):549-554
- CountryRepublic of Korea
- Language:English
- Abstract: Advances in oncology research have led to identification of tumor-specific biomarkers, some of which are important predictive indicators and ideal targets for novel therapeutics. One such biomarker in non-small cell lung cancer (NSCLC) is the epidermal growth factor receptor (EGFR). Patients with NSCLC who harbor an activating EGFR mutation show a more favorable response to treatment with an EGFR inhibitor, such as gefitinib, erlotinib, or afatinib, than to chemotherapy. The prevalence of EGFR mutations in East Asian patients is higher than that in other populations, and in some clinical settings, patients have been treated with EGFR inhibitors based on clinicopathologic characteristics with no information on EGFR status. However, based on results from a series of studies in which East Asian patients with advanced non-squamous NSCLC were treated with EGFR inhibitors alone or in combination with standard chemotherapy, this may not be the best practice because EGFR mutation status was found to be a key predictor of outcome. Data from these studies highlight the necessity of EGFR testing in determining the most suitable treatment for patients with advanced or metastatic NSCLC.
